PubMed · 5044925
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
H Yokoo. 1972-08-31. Smiling mitochondrion.. https://doi.org/10.1056/nejm197208312870918
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
Macrophage-derived chemokine (MDC), a potent chemoattractant for chronically activated Th2 lymphocytes, is constitutively expressed by dendritic cells, B cells, macrophages, and thymic medullary epithelial cells, whereas monocytes, NK cells, and T lymphocytes produce MDC only upon appropriate stimulation. In this study, we show in vitro MDC production also by activated T cells, which preferentially associate with the production of Th2 cytokines, IL-4, IL-5, and IL-6, and inversely correlate with the production of the Th1 cytokine, IFN-gamma. Moreover, high levels of MDC were detected in the sera of the great majority of subjects suffering from mycosis fungoides/Sézary syndrome or atopic dermatitis, which are considered as disorders characterized by the predominant expansion and activation of Th2 cells, respectively. By contrast, serum MDC levels in subjects with multiple sclerosis or Crohn's disease, which are characterized by a Th1 predominance, did not differ significantly from those of healthy controls. Finally, MDC expression was detected in the skin biopsy specimens of subjects with atopic dermatitis, where it was expressed by both dendritic cells and T lymphocytes. Taken together, these findings suggest that MDC production by activated T cells may occur both in vitro and in vivo, particularly in association with Th2 cytokines, thus providing an important amplification circuit for Th2-mediated responses.
Explore the source record for details and available documents.
INTRODUCTION: Diagnosis of extraluminal recurrent rectal cancer may be difficult. Currently the diagnosis is based on routine imaging procedures. Diagnosis often remains unverified until histological proof can be acquired by transcutaneous biopsy or operative exploration. The diagnostic value of positron emission tomography (PET) in recurrent rectal cancer was evaluated in a prospective study at the Department of Surgery of the RWTH Aachen University Hospital. The aim of the study was to assess the sensitivity of PET in the detection of recurrent rectal cancer in comparison with conventional procedures. Furthermore, the valency of PET in the diagnosis of the local expansion and metastasis was evaluated. METHODS: Since June 1997, PET has been performed in all patients with suspected recurrent rectal cancer. The examined area reaches from the neck to the symphysis. Visual assessment follows transversal, frontal and sagittal sector scans. Enhanced focal FDG uptake over the physiological enrichment of the environment (e.g., urinary tract) was defined as a criterion of malignancy. The findings were compared with the results of routine diagnosis and histological examinations. RESULTS: Up to now, 23 patients have been subjected to a PET examination. In 17 cases, a local recurrence could be proved. An intrahepatic metastasis was found in 11 patients, pulmonary metastasis in 3 patients, lymph-node metastasis in 5 patients, and a peritoneal carcinomatosis was found in 4 patients. All these findings were confirmed by histological examinations after biopsy and operation or by other imaging procedures and the clinical follow-up. CONCLUSIONS: The controlled results show that PET can detect recurrent rectal cancer and its metastasis with great precision. PET seems to be a useful additional examination in the diagnosis of extraluminal recurrent rectal cancer.